文献速递肥胖与代谢综合征

循环microRNA-122水平与减重干预下肝脏脂肪变化:CENTRAL试验

Circulating Levels of microRNA-122 and Hepatic Fat Change in Response to Weight-Loss Interventions: CENTRAL Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

CENTRAL试验为18个月随机对照试验,纳入腹部肥胖或血脂异常成人,比较低脂饮食与地中海/低碳水化合物饮食,6个月后各组再随机加或不加体力活动。220名基线及134名重复测量参与者中,血清miR-122从基线至18个月显著升高,4组间无差异;基线miR-122每增加1个对数单位与肝脏脂肪含量高3.79相关(P<0.001),miR-122升高越多者肝脏脂肪减少越少(β=1.56,P=0.002)。

要点

  • 血清miR-122从基线至18个月显著升高,4个干预组间无差异。
  • 基线log-miR-122每增加1单位与肝脏脂肪含量高3.79相关(P<0.001)。
  • miR-122升高越多者18个月肝脏脂肪减少越少(β=1.56,P=0.002)。

核心结论

  • 血清miR-122升高较多的参与者从饮食和体力活动干预中减少肝脏脂肪的获益可能较少。

研究设计与样本

  • CENTRAL试验为18个月随机对照试验,纳入腹部肥胖或血脂异常成人。
  • 受试者随机分配至低脂饮食或地中海/低碳水化合物饮食,6个月饮食干预后每组再随机分为增加体力活动组或不增加体力活动组,持续12个月。
  • 当前研究纳入220名基线参与者及134名在18个月内重复测量血清miR-122和肝脏脂肪含量的参与者。

主要发现

  • 血清miR-122从基线至18个月显著升高,4个干预组间无差异。
  • 基线时miR-122与肝脏脂肪含量显著相关,log转换后miR-122每增加1单位与肝脏脂肪含量高3.79相关(P<0.001)。
  • 18个月干预期间,miR-122升高越多与肝脏脂肪百分比减少越少相关(β=1.56,P=0.002)。
  • miR-122变化与基线空腹血糖对18个月肝脏脂肪含量变化存在显著交互作用(P交互=0.02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Little is known about the relations between changes in circulating microRNA-122 (miR-122) and liver fat in response to weight-loss interventions. We aimed to investigate the association between miR-122 and changes of hepatic fat content during 18-month diet and physical activity interventions. METHODS: The CENTRAL trial is an 18-month randomized, controlled trial among adults with abdominal obesity or dyslipidemia. Subjects were randomly assigned to a low-fat diet or a Mediterranean/low-carbohydrate diet. After 6 months of dietary intervention, each diet group was further randomized into added physical activity groups or no added physical activity groups for the following 12 months of intervention. The current study included 220 participants at baseline and 134 participants with repeated measurements on serum miR-122 and hepatic fat content over 18 months. RESULTS: Serum miR-122 significantly increased from baseline to 18 months, while no difference was observed across the 4 intervention groups. We found a significant association between miR-122 and hepatic fat content at baseline, as per unit increment in log-transformed miR-122 was associated with 3.79 higher hepatic fat content (P < 0.001). Furthermore, we found that higher elevations in miR-122 were associated with less reductions in hepatic fat percentage during 18-month interventions (β = 1.56, P = 0.002). We also found a significant interaction between changes in miR-122 and baseline fasting plasma glucose with hepatic fat content changes in 18 months (P interaction = 0.02). CONCLUSIONS: Our data indicate that participants with higher elevation in serum miR-122 may benefit less in reduction of hepatic fat content in response to diet and physical activity interventions.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang M, Xue Q, Li X, et al. Circulating Levels of microRNA-122 and Hepatic Fat Change in Response to Weight-Loss Interventions: CENTRAL Trial. J Clin Endocrinol Metab. 2022. PMID: 35037057. doi:10.1210/clinem/dgac023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。